Press Release
Farm animal pain relief product Tri–Solfen® achieves Australian government registration
December 19, 2011
In a world first on 14 December 2011, Animal Ethics Pty Ltd received full Australian Government registration for sheep pain relief product Tri-Solfen®, issued by the APVMA (Australian Pesticide Veterinary Medicine Authority) after 7 years of rigorous research and extensive use on lambs undergoing the controversial mulesing practice.
Since 2005, over 25 million merino lambs undergoing surgical mulesing have been treated with Tri-Solfen® under a special interim permit issued by the APVMA. Since this time Australian Veterinarians have been monitoring and helping to educate the nation’s farmers in Best Animal Welfare practices. This permit and the ongoing rigorous research into the safety and effectiveness of Tri-Solfen® led to the Australian Government granting full registration of the product.
The final registration details recorded the fact that Tri-Solfen® is totally safe to use on wool producing sheep and has no risk to humans, meat trade or the sheep being treated.
Tri-Solfen® was funded by the privately owned company Animal Ethics and received no woolgrower levies. A commercial outcome based on sound science and strong business principles.
Tri-Solfen® is the first product of its kind in the farming world. It is a unique, highly effective, safe and practical to use pain relief & wound healing medication. It is topically applied by the farmer, allowing for a convenient and very low cost solution for farmers wishing to undertake Best Animal Welfare practices.
Other farming sectors, nationally and internationally have now approached Animal Ethics to fast track research and registrations for products that address new welfare standards and higher consumer expectations, for farm animals undergoing dehorning, castration, branding or tail docking, with a sensible interest in being proactive in meeting new markets rather than reactive.
Over 1 billion farm animals globally undergo painful husbandry procedures every year without any form of pain relief. Animal Ethics is now well positioned to capitalise on new emerging markets and will seek investment partners to assist with the fast tracking of product registrations for other species that will meet surging demands from consumers, farming sectors and animal welfare groups.
– Ends –
About Medical Ethics
Medical Ethics is a commercial and development stage company focused on pain mitigation in wounds for humans and animals.
Through our proven patent protected platform technology, we have identified a transformational way of mitigating pain and minimising suffering associated with wounds.
About Tri-Solfen®
Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.
Further information
Medical Ethics:
Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286
FTI Consulting:
Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000
